The most important upcoming catalyst in neuroscience is Eli Lilly's TRAILBLAZER-ALZ 3 study, which aims to prevent Alzheimer's in at-risk patients. A positive result is expected to show a much larger effect size than seen in treating existing disease, potentially creating a massive new market and shifting the entire neurodegenerative paradigm.

While diet and exercise are often cited, neurobiologist Al Sandrock emphasizes sleep for Alzheimer's prevention. The brain has a natural clearance system that removes amyloid protein—a key culprit in the disease—during sleep. Therefore, consistently getting good sleep is a critical lifestyle intervention.

Alzheimer's is a disease of midlife. Pathological changes in the brain start to occur from around age 30, but the first noticeable cognitive symptoms typically don't manifest until one's late 60s or 70s. This highlights a crucial, multi-decade window for prevention and intervention.

The company's approach to Alzheimer's is a complete system, not just a drug. By leveraging Roche's diagnostic arm, they are pairing a new treatment with a simple, blood-based biomarker test for primary care physicians. This strategic pairing enables earlier patient identification, creating a more effective and accessible treatment paradigm.

The focus in Alzheimer's treatment is moving from merely slowing decline in late-stage patients to early prevention. By using anti-amyloid drugs to clear plaques before significant brain damage occurs, it may be possible to prevent the disease's onset entirely.

Voyager CEO Al Sandrock suggests the 30% average efficacy of new Alzheimer's drugs isn't uniform. Instead, some patients may see a complete halt in progression while others see no benefit. He argues the next critical step is predicting these responders, which will determine whether future therapies like anti-tau agents should be added on or used as a replacement.

The next era of CNS drug development will shift from single-target therapies for late-stage disease to early intervention. This involves using biomarkers to detect disease before symptoms appear and intervening with multimodal approaches that address multiple biological pathways simultaneously, such as amyloid, tau, and metabolic deficits in Alzheimer's.

Despite common belief, only about 3-5% of Alzheimer's cases are driven by inherited genetic mutations. The vast majority are linked to lifestyle factors like diet, exercise, and sleep, making it a largely preventable disease if proactive measures are taken early in life.

Current healthcare spending, or "Aging 1.0," focuses on managing age-related decline via retirement homes and late-stage care. The new paradigm, "Aging 2.0," uses biotechnology to prevent the need for this maintenance in the first place, representing a fundamental strategic shift.